发明名称 Biomarkers and methods for determining disease progression in nonalcoholic steatohepatitis (NASH)
摘要 Diets high in saturated fat and fructose have been implicated in the development of obesity and nonalcoholic steatohepatitis (NASH) in humans. Provided herein are biomarkers, methods, and animal models useful for the investigation and non-invasive detection of NASH, including a non-invasive biomarker that could be used to establish disease severity, follow progression, and evaluate response to treatment in clinical trials for this increasingly prevalent disease.
申请公布号 US8871454(B2) 申请公布日期 2014.10.28
申请号 US201113014580 申请日期 2011.01.26
申请人 Children's Hospital Medical Center 发明人 Kohli Rohit;Xanthakos Stavra A.;Miles Michael V.
分类号 G01N33/53;G01N31/00;G01N33/573 主分类号 G01N33/53
代理机构 Knobbe Martens Olson & Bear LLP 代理人 Knobbe Martens Olson & Bear LLP
主权项 1. A method of determining the presence of fatty liver disease (FLD) in a patient, comprising: providing a sample from a patient; measuring the level of coenzyme Q (CoQ) in the sample; and comparing the CoQ value from the patient with a threshold value, wherein if the CoQ value meets the threshold value the patient is determined to be at risk for fatty liver disease.
地址 Cincinnati OH US